UP!
| 2016-07-07 | Upgrade | BMO Capital Markets | Market Perform to Outperform | $11.50 to $16.00 |
| 2016-07-06 | Reiterated Rating | Oppenheimer Holdings Inc. | Outperform | $15.00 to $16.00 |
| 2016-06-13 | Upgrade | Canaccord Genuity | Hold to Buy | $15.50 |
| 2016-06-13 | Boost Price Target | RBC Capital | Outperform | $15.00 to $17.00 |
| 2016-06-13 | Reiterated Rating | Piper Jaffray | Overweight | $15.00 |
| 2016-06-13 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $15.00 |
| 2016-06-13 | Boost Price Target | Royal Bank Of Canada | Outperform | $15.00 to $17.00 |
| 2016-06-08 | Initiated Coverage | Guggenheim | Buy | $16.00 |
| 2016-05-29 | Reiterated Rating | BTIG Research | Buy | |
| 2016-05-10 | Reiterated Rating | BMO Capital Markets | Hold | $11.50 |
| 2016-05-10 | Boost Price Target | RBC Capital | Outperform | $11.00 to $15.00 |
| 2016-05-10 | Reiterated Rating | Canaccord Genuity | Hold | |
| 2016-05-10 | Reiterated Rating | Oppenheimer | Buy | |
| 2016-05-10 | Reiterated Rating | Oppenheimer Holdings Inc. | Buy | |
| 2016-04-04 | Initiated Coverage | JPMorgan Chase & Co. | Overweight | $11.00 |
| 2016-02-23 | Reiterated Rating | BTIG Research | Buy | $14.00 |
| 2016-02-23 | Reiterated Rating | Canaccord Genuity | Hold | $12.00 to $8.25 |
| 2016-02-23 | Lower Price Target | RBC Capital | Outperform | $15.00 to $11.00 |
| 2016-02-22 | Lower Price Target | Credit Suisse | Outperform | $16.00 to $10.00 |
| 2016-02-22 | Lower Price Target | Credit Suisse Group AG | Outperform | $16.00 to $10.00 |
| 2016-02-02 | Lower Price Target | Stifel Nicolaus | Buy | $17.00 to $15.00 |
| 2015-11-20 | Reiterated Rating | Canaccord Genuity | Hold | $12.00 |
| 2015-11-17 | Lower Price Target | RBC Capital | Outperform | $17.00 to $15.00 |
| 2015-11-03 | Reiterated Rating | Piper Jaffray | Overweight | $20.00 to $15.00 |
| 2015-10-27 | Reiterated Rating | BTIG Research | Buy | |
| 2015-10-27 | Reiterated Rating | Oppenheimer | Buy | $17.00 |
| 2015-10-27 | Lower Price Target | Credit Suisse | Outperform | $17.00 to $16.00 |
| 2015-10-27 | Reiterated Rating | Canaccord Genuity | Hold | $14.00 |
| 2015-10-27 | Downgrade | BMO Capital Markets | Outperform to Market Perform | $16.00 to $12.00 |
| 2015-10-19 | Initiated Coverage | RBC Capital | Outperform | $17.00 |
| 2015-10-09 | Lower Price Target | BMO Capital Markets | $17.00 to $16.00 | |
| 2015-09-28 | Upgrade | BTIG Research | Neutral to Buy | $16.00 |
| 2015-09-14 | Reiterated Rating | Oppenheimer | Outperform | $17.00 |
| 2015-08-27 | Reiterated Rating | Piper Jaffray | Overweight | $20.00 |
| 2015-08-07 | Upgrade | Oppenheimer | Market Perform to Outperform | |
| 2015-08-06 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | $15.00 to $17.00 |
| 2015-08-05 | Reiterated Rating | BMO Capital Markets | Buy | |
| 2015-08-04 | Lower Price Target | BMO Capital Markets | Outperform | $18.00 to $17.00 |
| 2015-08-04 | Reiterated Rating | Oppenheimer | Market Perform to Market Perform | $17.00 |
| 2015-08-04 | Reiterated Rating | BTIG Research | Hold | |
| 2015-08-04 | Lower Price Target | Piper Jaffray | Overweight | $21.00 to $20.00 |
| 2015-08-04 | Downgrade | Canaccord Genuity | Buy to Hold | $18.50 to $14.00 |
| 2015-08-04 | Lower Price Target | Stifel Nicolaus | Buy | $20.00 to $17.00 |
| 2015-06-17 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-06-15 | Reiterated Rating | Piper Jaffray | Overweight | $21.00 |
| 2015-05-27 | Reiterated Rating | Canaccord Genuity | Buy | $18.50 |
| 2015-05-04 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-04-30 | Reiterated Rating | Canaccord Genuity | Buy | $18.50 |
| 2015-04-30 | Boost Price Target | Oppenheimer | Market Perform | $15.00 to $17.00 |
| 2015-04-06 | Boost Price Target | Stifel Nicolaus | Buy | $17.00 to $20.00 |
| 2015-02-26 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-02-26 | Initiated Coverage | Canaccord Genuity | Buy | $20.00 |
| 2015-02-26 | Boost Price Target | JPMorgan Chase & Co. | Neutral | $14.00 to $15.00 |
| 2015-02-26 | Boost Price Target | Stifel Nicolaus | Buy | $15.00 to $17.00 |
| 2015-01-08 | Downgrade | BTIG Research | Buy to Neutral | |
| 2014-12-29 | Boost Price Target | Piper Jaffray | Overweight | $18.00 to $21.00 |
| 2014-10-31 | Reiterated Rating | Canaccord Genuity | Buy | $17.50 to $17.00 |
| 2014-10-01 | Reiterated Rating | Credit Suisse | Outperform | $19.00 to $17.00 |
| 2014-10-01 | Lower Price Target | Stifel Nicolaus | Buy | $17.00 to $15.00 |
| 2014-10-01 | Lower Price Target | Oppenheimer | Market Perform | $15.00 to $13.00 |
| 2014-08-25 | Upgrade | BTIG Research | Neutral to Buy | $17.00 |
| 2014-07-31 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $15.00 to $17.00 |
| 2014-07-29 | Initiated Coverage | Credit Suisse | Outperform | |
| 2014-07-07 | Downgrade | BTIG Research | Buy to Neutral | |
| 2014-06-30 | Initiated Coverage | Credit Suisse | Outperform | $19.00 |
| 2014-05-12 | Initiated Coverage | JPMorgan Chase & Co. | Neutral | $15.00 |
| 2014-05-01 | Reiterated Rating | Oppenheimer | Market Perform | $15.00 |
| 2014-03-21 | Upgrade | BTIG Research | Neutral to Buy | $15.00 |
| 2014-02-28 | Lower Price Target | Canaccord Genuity | Buy | $22.00 to $17.50 |
| 2014-02-28 | Downgrade | BTIG Research | Buy to Neutral | $21.00 |
| 2014-02-28 | Downgrade | Oppenheimer | Outperform to Market Perform | $20.00 to $16.00 |
| 2014-01-07 | Initiated Coverage | BTIG Research | Buy | |
| 2013-12-04 | Reiterated Rating | Canaccord Genuity | Accumulate | $22.00 |
| 2013-11-01 | Boost Price Target | Stifel Nicolaus | Buy | $18.00 to $20.00 |
| 2013-10-31 | Boost Price Target | Canaccord Genuity | Buy | $19.00 to $22.00 |
| 2013-10-31 | Reiterated Rating | BMO Capital Markets | Outperform | $18.00 to $20.00 |
| 2011-01-14 | Initiated | Robert W. Baird | Outperform | $9 |
| 2009-08-10 | Initiated | Piper Jaffray | Neutral | |
| 2009-07-02 | Initiated | Lazard Capital Mkts | Buy | $6 |
| 2007-05-23 | Initiated | Dawson James | Buy | $5.50 |
| 2016-07-07 | Upgrade | BMO Capital Markets | Market Perform to Outperform | $11.50 to $16.00 |
| 2016-07-06 | Reiterated Rating | Oppenheimer Holdings Inc. | Outperform | $15.00 to $16.00 |
| 2016-06-13 | Upgrade | Canaccord Genuity | Hold to Buy | $15.50 |
| 2016-06-13 | Boost Price Target | RBC Capital | Outperform | $15.00 to $17.00 |
| 2016-06-13 | Reiterated Rating | Piper Jaffray | Overweight | $15.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ELGX 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| ESSEX WOODLANDS HEALTH VENTURES FUND VII LP | 1.74% (1165428) | ELGX / LJPC / |
| McDermott John D Chief Executive Officer | 1.25% (838659) | ELGX / |
| Chavez Christopher G. | 0.57% (378362) | ELGX / |
| Mitchell Robert D President, Global Initiatives | 0.47% (316886) | ELGX / |
| Chobotov Michael V. Chief Technology Officer | 0.28% (189269) | ELGX / |
| DeJohn Joseph A. Vice President - Sales | 0.23% (153471) | ELGX / |
| Krist Robert John Chief Financial Officer | 0.21% (142236) | ELGX / |
| Mahboob Vaseem Chief Financial Officer | 0.17% (116812) | ELGX / INSY / |
| Lemaitre Dan | 0.15% (102921) | ELGX / GMED / |
| SCHRECK STEFAN Vice President | 0.15% (97136) | ELGX / |
| O'Quinn Shari L VP, Clinical & Regulatory | 0.14% (94356) | ELGX / |
| Abraham Todd VP of Operations | 0.13% (86821) | ELGX / |
| NEELS GUIDO J | 0.13% (84202) | AXGN / ELGX / |
| Fauls Janet Mary Vice President RA/QA/QC | 0.12% (82492) | ELGX / |
| Zenty III Thomas F | 0.10% (69396) | ELGX / |
| Onopchenko John Chief Operating Officer | 0.08% (56604) | ELGX / VOLC / |
| Wilder Thomas | 0.08% (51060) | ELGX / |
| WALLER GREGORY D | 0.08% (50550) | BIOL / ELGX / SSH / |
| Jennings David M. VP-Human Resources | 0.08% (50281) | ELGX / |
| Nagel Laura VP, Quality | 0.07% (48860) | ELGX / |
| Love Charles Steele VP-Clinical Affairs | 0.07% (45037) | ELGX / |
| DePalma Amanda L. VP, Global Marketing | 0.07% (43772) | ELGX / |
| Norwalk Leslie V | 0.06% (43491) | ELGX / NUVA / PRSC / VOLC / |
| Machek James Edward VP-Research & Development | 0.06% (38286) | ELGX / |
| Lima Jose A. VP-Quality | 0.06% (37884) | ELGX / |
| Lyons Ruth Anne VP Global Marketing | 0.04% (27168) | ELGX / |
| Thunen Shelley B Chief Financial Officer | 0.03% (17143) | ELGX / |
| Tyler Martin V.P. Global Marketing | 0.02% (14472) | ELGX / |
| DE GREEF RODERICK | 0.01% (7102) | BLFS / ELGX / |
| Sorsher Gary I. Vice President - Quality | 0.01% (4704) | ELGX / |
UM